The Public Health Agency of Canada (PHAC) has entered into a five-year contract with Bavarian Nordic for the purchase of its smallpox vaccine ‘Imvamune’ for $56m. Imvamune, with the brand name of Jynneos in the US, and Imvanex in Europe, is approved for the treatment of monkeypox and smallpox vaccine in Canada and the US. In the rest of the world, Imvamune is used only against monkeypox. Bavarian Nordic will not be making deliveries before 2023, as per the contract.
Read More from Biopharma Reporter